Results 171 to 180 of about 17,302 (216)
The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option-Case Report. [PDF]
Issa R +7 more
europepmc +1 more source
A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma. [PDF]
Wei C +11 more
europepmc +1 more source
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. [PDF]
Sallman DA +25 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2005
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
BACKGROUND: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
Brian Leber, Roman Hajek, Su-Peng Yeh
exaly +2 more sources

